BLA 021629 · Sanofi Aventis US
Apidra Solostar
Insulin Glulisine Recombinant · Subcutaneous, Intravenous, Subcutaneous · Insulin Analog
NovelLast checked: Nov 20, 2026Latest source record: Nov 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Apr 16, 2004
Approved uses
3
Original approval plus efficacy supplements
Registered trials
98
28 Phase 3, 0 recruiting
FAERS reports
10,207
7,737 serious, 819 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 25, 2025.
APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )
Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 24, 2008 Supplement 15 · Efficacy LabelLetter
- Apr 12, 2007 Supplement 10 · Efficacy LetterLabel
- Apr 16, 2004 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPediatric Statistical Review
3 products under this application
- APIDRA SOLOSTAR · INSULIN GLULISINE RECOMBINANT 300 UNITS/3ML · INJECTABLE, SUBCUTANEOUS · Prescription
- APIDRA · INSULIN GLULISINE RECOMBINANT 1000 UNITS/10ML (100 UNITS/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription
- APIDRA · INSULIN GLULISINE RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Glulisine Recombinant" as an intervention, any sponsor and status, largest first.
- Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative StudyPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01121835 · 934 participants · Start Feb 2010 · Primary completion Mar 2012
Drug: INSULIN GLARGINE; INSULIN GLULISINE and 1 more · For: Diabetes Mellitus, Type 2
Sites: Sankt Stefan, Austria; Vienna, Austria; Belém, Brazil · 96 sites in all
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01768559 · 894 participants · Start Jan 2013 · Primary completion Dec 2014
Drug: Lixisenatide (AVE0010); Insulin glulisine QD and 3 more · For: Type 2 Diabetes
Sites: Sun City, Arizona; Tempe, Arizona; Little Rock, Arkansas · 199 sites in all
- Opposing Step-by-step Insulin Reinforcement to Intensified StrategyPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00174642 · 811 participants · Start Dec 2004 · Primary completion Dec 2008
Drug: Insulin Glargine; Insulin Glulisine and 2 more · For: Diabetes Mellitus, Type 2
Sites: Brussels, Belgium; Paris, France; Berlin, Germany · 18 sites in all
- A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes MellitusPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02688933 · 638 participants · Start May 5, 2016 · Primary completion Jun 19, 2017
Drug: HOE901-U300 (Insulin Glargine 300 U/ml); Lantus (Insulin Glargine 100 U/ml) and 1 more · For: Type 1 Diabetes Mellitus
Sites: Little Rock, Arkansas; Concord, California; Escondido, California · 100 sites in all
- Insulin Glargine "All to Target" TrialPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00384085 · 588 participants · Start May 2006 · Primary completion Mar 2010
Drug: Insulin Glulisine; Insulin Glargine and 2 more · For: Diabetes Mellitus, Type 2
Sites: Bridgewater, New Jersey
- Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00135941 · 582 participants · Start Aug 2005
Drug: insulin glargine; insulin glulisine · For: Diabetes Mellitus
Sites: Milwaukee, Wisconsin
- Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and AdolescentsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00115570 · 572 participants · Start Apr 2005 · Primary completion Nov 2006
Drug: Insulin glulisine; insulin lispro and 2 more · For: Diabetes Mellitus, Insulin-Dependent
Sites: Pittsburgh, Pennsylvania
- REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT00640991 · 500 participants (planned) · Start Apr 2008 · Primary completion Jun 2010
Drug: glulisine insulin, glargine insulin · For: Hyperglycemia; Cardiovascular Diseases; Myocardial Infarction
Sites: Adrogué, Argentina; Hamilton, Canada; Dt. Dibrugarh, India · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,577
- hypoglycaemia785
- hyperglycaemia655
- drug ineffective582
- blood glucose decreased455
- dizziness407
- malaise398
- dyspnoea393
- nausea380
- vomiting348
- acute kidney injury310
- fatigue310
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 73 |
| 2007 | 187 |
| 2008 | 119 |
| 2009 | 197 |
| 2010 | 291 |
| 2011 | 480 |
| 2012 | 513 |
| 2013 | 578 |
| 2014 | 867 |
| 2015 | 1,076 |
| 2016 | 615 |
| 2017 | 613 |
| 2018 | 968 |
| 2019 | 869 |
| 2020 | 576 |
| 2021 | 428 |
| 2022 | 470 |
| 2023 | 384 |
| 2024 | 345 |
| 2025 | 295 |
| 2026 | 254 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Apidra (Insulin Glulisine)
2024 spending
$735K
Beneficiaries
667
2,245 claims
Per beneficiary
$1,102
$8.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,528,780 |
| 2021 | $3,769,932 |
| 2022 | $3,030,250 |
| 2023 | $2,769,322 |
| 2024 | $735,198 |
Part D: Apidra Solostar (Insulin Glulisine)
2024 spending
$2.3M
Beneficiaries
2,523
8,018 claims
Per beneficiary
$910
$10.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,268,555 |
| 2021 | $10,338,191 |
| 2022 | $9,202,504 |
| 2023 | $8,643,475 |
| 2024 | $2,296,756 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Sanofi · Also marketed as Apidra
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.